Yong Shanshan, Yang Yali, Li Fuhao, Yao Hangyu, Yang Fang, Chang Degui
Hospital of Chengdu University of Traditional Chinese Medicine.
Department of Andrology, The Reproductive and Women-Children Hospital, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
Medicine (Baltimore). 2020 Aug 14;99(33):e21769. doi: 10.1097/MD.0000000000021769.
The incidence of male infertility is increasing worldwide, and has become an important problem that plagues many married couples. Half of the infertility cases have induced by male infertility. Wuzi Yanzong Pill is a traditional Chinese herbal formula used in treating spermatorrhea, premature ejaculation, erectile dysfunction, lumbago and male sterility widely. Therefore, in this systematic review, we design to evaluate the effectiveness and safety of Wuzi-Yanzong Pill for the treatment of male infertility.
The English and Chinese literature published before June 30, 2020 will be searched in PubMed, EMBASE, Cochrane library, and Chinese literature in China National Knowledge Infrastructure, Chinese biomedical document service system, VIP Chinese Science and Technology Journal Database, WANFANG data. All related randomized controlled trials that meet the eligibility criteria will be included and other studies will be excluded. We will search literature with text keywords "male infertility" or "sperm" or "semen" and "Wuzi Yanzong Pill" or "Wuziyangzong" or "WZYZ". Progressive motility, sperm concentration, sperm morphology, sperm viability, sperm DNA fragmentation, sperm number per ejaculate, pregnancy rates will be evaluated. RevMan 5.3 and Stata 14.0 will be used to conduct this systematic review. The preferred reporting items for systematic reviews and meta-analysis protocols statement is followed in this protocol and the PRISMA statement will be followed in the completed systematic review.
The efficacy and safety of Wuzi Yanzong Pill in the treatment of male infertility will be e evaluated. The results of this review may provide some help for the clinician's decision.
全球男性不育症的发病率正在上升，已成为困扰许多已婚夫妇的一个重要问题。不育病例中有一半是由男性不育引起的。五子衍宗丸是一种传统中药配方，广泛用于治疗遗精、早泄、勃起功能障碍、腰痛和男性不育症。因此，在本系统评价中，我们旨在评估五子衍宗丸治疗男性不育症的有效性和安全性。
将检索2020年6月30日前发表的英文和中文文献，检索数据库包括PubMed、EMBASE、Cochrane图书馆，以及中国知网、中国生物医学文献服务系统、维普中文科技期刊数据库、万方数据中的中文文献。将纳入所有符合纳入标准的相关随机对照试验，排除其他研究。我们将使用文本关键词“男性不育”或“精子”或“精液”以及“五子衍宗丸”或“五子养宗”或“WZYZ”检索文献。将评估精子前向运动率、精子浓度、精子形态、精子活力、精子DNA碎片率、每次射精的精子数量、妊娠率。将使用RevMan 5.3和Stata 14.0进行本系统评价。本方案遵循系统评价和Meta分析方案的首选报告项目声明，完成的系统评价将遵循PRISMA声明。
将评估五子衍宗丸治疗男性不育症的疗效和安全性。本评价结果可能为临床医生的决策提供一些帮助。
